Item 8.01. Other Events.
On
As previously disclosed, on
The Company intends to regain compliance with the applicable continued listing
requirements of Nasdaq prior to the end of the compliance period. However, until
Nasdaq has reached a final determination that the Company has regained
compliance with all of the applicable continued listing requirements, there can
be no assurances regarding the continued listing of the Company's common stock
on Nasdaq. In the event the Company does not evidence compliance prior to the
end of the compliance period, the Company may be subject to delisting. At that
time, the Company may appeal the Staff's determination to a
Forward-looking Statements
This current report on Form 8-K includes forward-looking statements based upon
the Company's current expectations. Forward-looking statements include, but are
not limited to, statements that express our intentions, beliefs, expectations,
strategies, predictions, anticipated milestones, and any other statements
relating to our future activities or other future events or conditions. These
statements are based on current expectations, estimates and projections about
our business based, in part, on assumptions made by management. Actual results
and the timing of events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and uncertainties, which
include, without limitation: uncertainties and risks related to our continued
listing on Nasdaq and the ability to access capital markets; our review of
strategic alternatives, and the results of such review; our need to raise
additional capital to fund our operations for at least the next 12 months as a
going concern and to advance our product candidates and preclinical programs,
including in light of current stock market conditions; risks related to our
ability to successfully implement our business plans, including reliance on our
lead product candidate; uncertainties associated with the clinical development
and regulatory approval of product candidates, including any delays associated
therewith; uncertainties in obtaining successful clinical results for product
candidates and unexpected costs that may result therefrom; risks related to the
failure to realize any value from product candidates and preclinical programs
being developed and anticipated to be developed in light of inherent risks and
difficulties involved in successfully bringing product candidates to market;
intellectual property risks; reliance on collaborators; reliance on research and
development partners; and risks related to cybersecurity and data privacy. These
and other risks and uncertainties are more fully described in periodic filings
with the
--------------------------------------------------------------------------------
© Edgar Online, source